Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Woon

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Urology|February 16, 2021
A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or EnzalutamideDixon T S Woon, Antonio Finelli, Douglas C Cheung, et al.
World Journal of Urology|May 16, 2019
Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorshipMarian S Wettstein, Clinsy Pazhepurackel, Aline S Neumann, et al.
Cancers|December 17, 2024
Snap Diagnosis: Developing an Artificial Intelligence Algorithm for Penile Cancer Detection from PhotographsJianliang Liu, Jonathan S O'Brien, Kishor Nandakishor, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Urologic Oncology|January 26, 2021
Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?Jaime O Herrera-Caceres, Alexandra Gleave, Katherine Lajkosz, et al.
ANZ Journal of Surgery|December 1, 2025
Outcomes of Radical Nephrectomy With Caval Tumour Thrombectomy Including a Novel Two-Stage ApproachDaniel Crisafi, Anne Hong, Nathan Papa, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
The Journal of Urology|February 19, 2020
A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank SpecimensDixon T S Woon, Jaime O Herrera-Cáceres, Hanan Goldberg, et al.
BJU International|April 25, 2025
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancerAndrew W Silagy, Dixon T S Woon, Louise Kostos, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 1, 2020
Utility of digital rectal examination in a population with prostate cancer treated with active surveillanceJaime O Herrera-Caceres, Marian S Wettstein, Hanan Goldberg, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Urology|February 16, 2021
A Population-based Study Comparing Outcomes for Patients With Metastatic Castrate Resistant Prostate Cancer Treated by Urologists or Medical Oncologists With First Line Abiraterone Acetate or EnzalutamideDixon T S Woon, Antonio Finelli, Douglas C Cheung, et al.
World Journal of Urology|May 16, 2019
Photoselective vaporization of the prostate: study outcomes as a function of risk of bias, conflicts of interest, and industrial sponsorshipMarian S Wettstein, Clinsy Pazhepurackel, Aline S Neumann, et al.
Cancers|December 17, 2024
Snap Diagnosis: Developing an Artificial Intelligence Algorithm for Penile Cancer Detection from PhotographsJianliang Liu, Jonathan S O'Brien, Kishor Nandakishor, et al.
BJU International|November 28, 2024
Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mLSamuel Sii, Nathan Papa, Ting Wai Yiu, et al.
Urologic Oncology|January 26, 2021
Defining oligometastatic hormone sensitive prostate cancer and clinically significant outcomes: Implications on clinical trials?Jaime O Herrera-Caceres, Alexandra Gleave, Katherine Lajkosz, et al.
ANZ Journal of Surgery|December 1, 2025
Outcomes of Radical Nephrectomy With Caval Tumour Thrombectomy Including a Novel Two-Stage ApproachDaniel Crisafi, Anne Hong, Nathan Papa, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 25, 2018
Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provincesDixon T S Woon, Thenappan Chandrasekar, Lorne Aaron, et al.
The Journal of Urology|February 19, 2020
A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank SpecimensDixon T S Woon, Jaime O Herrera-Cáceres, Hanan Goldberg, et al.
BJU International|April 25, 2025
Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancerAndrew W Silagy, Dixon T S Woon, Louise Kostos, et al.
Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|April 1, 2020
Utility of digital rectal examination in a population with prostate cancer treated with active surveillanceJaime O Herrera-Caceres, Marian S Wettstein, Hanan Goldberg, et al.
Pageof 4